Medical Device Software Escrow: FDA Compliance and Risk Mitigation...

A hospital’s infusion pump software freezes mid-shift. A diagnostic imaging platform throws an error code nobody on staff has seen before. A remote patient monitoring app stops syncing data to the cloud dashboard a cardiology group depends on for early warning alerts. In each case, the fix isn’t really about the bug – it’s about who can access the source code, how fast they can act, and whether the software vendor is even still around to help.

Medical device software occupies a strange middle ground in enterprise risk management. It’s regulated like a physical product, but it behaves like software, which means it changes, breaks, and ages the way all software does. For CIOs, compliance officers, and risk managers in healthcare, that combination creates a continuity problem that generic IT risk frameworks don’t fully address. This article looks at where that risk lives, how regulatory expectations intersect with software governance, and where software escrow fits into a broader continuity strategy.

Why Medical Device Software Is a Different Risk Category

Traditional enterprise software risk management assumes a certain amount of flexibility. If a vendor goes dark, you can often migrate, patch around the gap, or bring in a systems integrator to reverse-engineer a workaround. Medical device software rarely affords that flexibility.

Software embedded in or controlling a regulated medical device is typically validated as part of that device’s design history file. Changing it, patching it, or replacing it isn’t a simple IT decision. It can trigger revalidation requirements and, in some cases, a new regulatory submission. The FDA’s guidance on software as a medical device (SaMD) and its expectations around software lifecycle processes (drawing heavily on standards like IEC 62304) mean that the software is a part of the regulated article itself.

That changes the risk calculus. A vendor bankruptcy or an acquisition that quietly deprioritizes a product line doesn’t just create an inconvenience. It can leave a healthcare provider holding a regulated device with no ability to patch a vulnerability, fix a defect, or even fully understand how the software behaves under edge-case conditions.

Software developers building these systems know this. Enterprise architects at hospital networks and health systems increasingly ask about it during procurement. But the answer often stops at “we have a support contract,” which addresses a very different kind of failure than vendor disappearance or insolvency.

The Compliance Layer: What Regulators Actually Expect

It’s worth separating two distinct pressures here, because they get conflated often: what regulators require, and what good software governance recommends.

FDA’s quality system regulation (21 CFR Part 820, now largely harmonized with ISO 13485 under the amended Quality Management System Regulation) doesn’t explicitly mandate source code escrow. No regulation does, as a blanket rule. What the regulation does require is that manufacturers maintain control over their design history and demonstrate an ability to support the device throughout its lifecycle, including corrective and preventive action (CAPA) processes tied to software defects.

This is where things get interesting for healthcare provider organizations and medical device manufacturers alike. If a manufacturer relies on a third-party software vendor for a critical component, such as an embedded RTOS, a cloud connectivity module, or an AI-based diagnostic algorithm, that manufacturer still bears regulatory responsibility for the finished device.

Compliance teams and legal counsel reviewing these arrangements are increasingly asking a pointed question: if this vendor disappeared tomorrow, could we still meet our corrective action obligations? For a growing number of manufacturers, the honest answer is no, at least not without a plan.

Postmarket surveillance adds another layer. The FDA expects manufacturers to monitor real-world performance and respond to signals of malfunction or harm. Responding meaningfully sometimes requires access to source code, build environments, or engineering documentation that lives entirely with a third-party vendor. Regulatory and compliance considerations here aren’t hypothetical. They surface during audits, during 510(k) or PMA submissions that reference third-party components, and during FDA inspections that probe supplier controls.

Where Vendor Dependency Risk Actually Bites

Enterprise risk management frameworks talk about vendor dependency risk in fairly abstract terms. In medical device software, it shows up in specific, uncomfortable ways.

Consider a mid-sized manufacturer of continuous glucose monitoring devices that licenses its data analytics engine from a small analytics startup. Two years in, the startup gets acquired by a larger firm that’s really only interested in the customer list, not the product line. Support quality degrades. Then it stops.

The manufacturer now has a device on the market, patients relying on it, and no practical way to maintain the analytics component that regulators consider part of the validated system. Switching vendors means requalifying the entire data pipeline, which is not a weekend project. Reverse-engineering the code without documentation or historical build environments is realistically not viable in any acceptable timeframe.

This is a disaster recovery planning problem as much as it is a legal one. And it’s exactly the kind of scenario that source code access planning is meant to address before it happens.

Procurement and vendor management teams are usually the first line of defense here, and procurement due diligence for medical device software components deserves more rigor than it typically gets. A vendor’s financial stability, its succession planning, and its own dependency on subcontractors all deserve scrutiny before a contract is signed, not after a warning sign appears. Technology governance frameworks that treat this component-level scrutiny as optional tend to discover the gap at the worst possible moment.

Business Continuity Planning for Regulated Software

Business continuity planning in a hospital or health system context usually focuses on facilities, staffing, and clinical workflow redundancy. Software continuity planning for medical devices needs its own dedicated lane, because the failure modes and remediation paths are different.

A few questions tend to separate organizations with a mature continuity posture from those that are exposed:

Do we know exactly which vendors control the code for FDA-regulated components of our device portfolio? This sounds basic, but enterprise architecture teams at larger health systems and manufacturers are often surprised by how fragmented this picture is once they map it out. Software gets embedded, licensed, and inherited through acquisitions faster than governance documentation keeps up.

If a vendor became unresponsive tomorrow, what’s our actual timeline to functional continuity? A real answer involves access to source code, build instructions, dependency documentation, and someone who understands the codebase well enough to compile and validate it.

Who has visibility into this risk, and is it actually documented anywhere? DevOps continuity planning tends to be strong for internally developed systems and weak for anything licensed from outside vendors, simply because internal teams don’t control the release cadence or documentation practices of a third party.

Answering these honestly usually reveals gaps. It reflects how quickly the medical device software landscape has grown more complex, with more embedded third-party components, more cloud dependencies, and more AI-driven features than the continuity frameworks built a decade ago were designed to handle.

The Role of Software Escrow in This Picture

This is where software escrow becomes relevant, though it’s worth being precise about what it does and doesn’t solve.

Software escrow is an arrangement, typically involving a neutral third party, where a vendor’s source code and associated materials are deposited and held in trust. If specific, contractually defined release conditions occur, such as vendor insolvency, abandonment of the product, or failure to meet support obligations, the licensee gains access to the deposited materials. It’s a contractual and legal mechanism, not a technical one, though the deposited materials themselves are technical.

For medical device manufacturers relying on third-party software components, escrow verification is arguably more important than the deposit itself. A deposit that turns out to be an incomplete or outdated codebase, missing build scripts, configuration files, or dependency manifests, provides false comfort. Escrow verification services test whether the deposited materials can actually be built and whether they match what’s running in production. For regulated software, where CAPA obligations and postmarket surveillance depend on being able to actually work with the code, verification isn’t a nice-to-have. It’s the difference between a real safety net and a document nobody can use.

This matters just as much for SaaS-delivered components. A growing share of medical device software, particularly the analytics, connectivity, and AI layers, is delivered as SaaS rather than installed software. SaaS escrow arrangements need to account for infrastructure-as-code, database schemas, API configurations, and sometimes trained model weights, not just a source code repository. A continuity plan built around traditional software escrow alone can miss these components entirely if the escrow agreement wasn’t scoped with SaaS delivery in mind.

None of this replaces the manufacturer’s own quality system obligations. Escrow doesn’t validate software, doesn’t satisfy CAPA requirements on its own, and doesn’t substitute for a documented risk management process under ISO 14971. What it does is close a specific gap: the scenario where a vendor is gone, and there’s otherwise no legal or practical path to the materials needed to keep a regulated device supportable.

Building Escrow Into a Broader Governance Strategy

Third-party software governance works best as a layered approach, and escrow sits alongside several other controls rather than standing in for them.

Contractual protections matter first. Support and maintenance obligations, source code ownership or license terms, and clearly defined escrow release conditions should be negotiated as part of the original agreement, not added as an afterthought once a vendor relationship shows signs of strain. Legal counsel involved early in vendor negotiations can often secure better escrow terms than counsel brought in after a relationship has already deteriorated.

Documentation requirements come next. An escrow deposit is only as useful as what accompanies it. Build instructions, dependency lists, test suites, and architectural documentation determine whether a deposit is a genuine continuity asset or a folder of source files nobody can compile. This is where the practical mechanics of automated escrow arrangements offer a real advantage: automated deposit processes that sync directly with a vendor’s development environment or repository reduce the risk of stale, incomplete, or manually neglected deposits, which historically have been one of the biggest failure points in traditional escrow relationships.

Ongoing verification closes the loop. A deposit made once, at contract signing, and never updated or tested again tells you almost nothing about whether the materials will actually work when needed years later, especially as the vendor’s product evolves through updates and patches.

Retention policy deserves specific attention in this industry. Medical devices often stay in clinical use for many years, sometimes over a decade, well beyond typical commercial software lifecycles. An escrow arrangement with a limited retention window can quietly expire long before the device it was meant to protect leaves the field. For regulated software with long service lives, retention terms need to match the realistic lifespan of the device, not a generic commercial software refresh cycle.

Jurisdiction and legal enforceability round out the picture. Escrow agreements are only as strong as the legal system that would enforce a release. For U.S. healthcare organizations and manufacturers, an escrow arrangement governed under U.S. law, with a U.S.-based escrow agent, removes a layer of legal complexity and uncertainty that can otherwise slow down a release exactly when speed matters most.

A Practical Framework for Risk and Compliance Teams

For organizations trying to operationalize this rather than just think about it abstractly, a few starting points tend to be useful.

Start with an inventory of third-party software components embedded in or supporting regulated devices, and rank them by both regulatory criticality and vendor risk. A small, single-product vendor supplying a component that’s core to device function deserves more scrutiny than a large, diversified vendor supplying something peripheral.

From there, map existing contractual protections against that inventory. Many organizations discover that escrow language exists in some agreements but not others, with wildly inconsistent terms: some with real verification provisions, some with vague “best efforts” deposit language that would be difficult to enforce if it ever mattered.

Finally, treat this as a living process rather than a one-time audit. Vendor relationships change, acquisitions happen, and product roadmaps shift. A continuity strategy that was solid two years ago can develop blind spots quietly, without any single dramatic event marking the moment it happened.

Where This Leaves Manufacturers and Healthcare Organizations

None of this is about assuming vendors will fail. Most won’t. But the cost of being wrong in medical device software, where patient safety and regulatory standing are both on the line, is high enough that “probably fine” isn’t a strategy compliance and risk teams can stand behind.

This is the space where PRAXIS’s Escrow Assurance™ approach was built to operate. Combining Automated Escrow with continuous, verified deposits means the materials sitting in escrow actually reflect what’s running in production, rather than a snapshot from a contract signing years earlier. Infinite Retention addresses the long service life that’s typical of medical devices. It removes the risk of a retention window lapsing before the device it protects has left the field. U.S.-based jurisdiction gives healthcare organizations and manufacturers a predictable legal framework if a release ever becomes necessary, and transparent, all-inclusive pricing means the cost of that protection is known upfront rather than buried in change orders down the line.

Escrow won’t replace a manufacturer’s quality system, and it won’t satisfy every regulatory expectation on its own. But as one component of a broader continuity, governance, and risk management strategy, it addresses a real and specific gap that is too expensive to neglect.